A. Sinclair Dunlop - 25 Aug 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
25 Aug 2022
Net transactions value
+$56,796
Form type
4
Filing time
26 Aug 2022, 16:06:05 UTC
Previous filing
17 Aug 2022
Next filing
08 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $56,796 +4,306 +3.4% $13.19 130,430 25 Aug 2022 Direct
holding APLS Common Stock 255,679 25 Aug 2022 Indirect Owner (Epidarex) F1
holding APLS Common Stock 31,855 25 Aug 2022 Indirect Owner (Masa) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -4,306 -24% $0.000000 13,274 25 Aug 2022 Common Stock 4,306 $13.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F2 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
F3 This option was granted on January 1, 2019 and fully vested.